Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Vir Biotechnology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:03.520 Reminder, this conference call is being recorded. 00:00:03.520 -- 00:00:07.840 At this time, all participants are in a listen-only mode. 00:00:07.840 -- 00:00:12.080 After the speaker's remarks, there will be a question and answer session. 00:00:12.080 -- 00:00:16.660 I will now turn the call over to Rich Lefke, Senior Director, Investor Relations. 00:00:16.660 -- 00:00:19.600 You may begin, Mr. Lefke. 00:00:20.180 -- 00:00:22.840 Thank you, and good afternoon. With me today are Dr. 00:00:22.840 -- 00:00:25.820 Marianne DeBacker, our Chief Executive Officer, Dr. 00:00:25.820 -- 00:00:30.820 Mark Eisner, our Chief Medical Officer, Jason O'Byrne, our Chief Financial Officer, and 00:00:30.820 -- 00:00:35.040 Dr. Mika During, our Executive Vice President of Oncology, who will be available during 00:00:35.040 -- 00:00:37.060 the Q&A session. 00:00:37.060 -- 00:00:40.640 Before we begin, I would like to remind everyone that some of the statements we are making 00:00:40.640 -- 00:00:44.700 today are forward-looking statements under the securities laws. 00:00:44.700 -- 00:00:49.200 These forward-looking statements involve substantial risks and uncertainties that could 00:00:49.200 -- 00:00:53.600 cause our clinical development programs, future results, performance, or achievements 00:00:53.600 -- 00:00:58.920 to differ significantly from those expressed or implied by such forward-looking statements. 00:00:58.920 -- 00:01:03.660 These risks and uncertainties and risks associated with our business are described in 00:01:03.660 -- 00:01:07.520 the company's reports filed with the Securities and Exchange Commission, including Forms 00:01:07.520 -- 00:01:12.560 10-K, 10-Q, and 8-K. I will now turn the call over to our CEO, 00:01:12.560 -- 00:01...